

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
31 March 2022 (31.03.2022)



(10) International Publication Number
WO 2022/064399 A1

(51) International Patent Classification:

A61P 35/00 (2006.01) A61K 39/00 (2006.01)
A61K 39/395 (2006.01) C07K 16/30 (2006.01)

Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))

(21) International Application Number:

PCT/IB2021/058662

Published:

— with international search report (Art. 21(3))
— with sequence listing part of description (Rule 5.2(a))
— in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE

(22) International Filing Date:

22 September 2021 (22.09.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/082,162 23 September 2020 (23.09.2020) US
63/084,900 29 September 2020 (29.09.2020) US

(71) Applicant: **MEDIMMUNE, LLC** [US/US]; One MedImmune Way, Gaithersburg, Maryland 20878 (US).

(72) Inventors: **KUMAR, Rakesh**; c/o MedImmune, LLC, One MedImmune Way, Gaithersburg, Maryland 20878 (US). **ENGLERT, Judson**; c/o MedImmune, LLC, One MedImmune Way, Gaithersburg, Maryland 20878 (US). **COOPER, Zachary**; c/o MedImmune, LLC, One MedImmune Way, Gaithersburg, Maryland 20878 (US). **MARTIN, Philip Lloyd**; c/o MedImmune, LLC, One MedImmune Way, Gaithersburg, Maryland 20878 (US).

(74) Agent: **XUE, Xiaoxiao**; MedImmune, LLC, One MedImmune Way, Gaithersburg, Maryland 20878 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: TREATMENT METHODS USING ANTI-CD73 AND ANTI-PD-L1 ANTIBODIES AND CHEMOTHERAPY

(57) Abstract: This disclosure relates to methods of treating cancers in a human patient (e.g., metastatic pancreatic ductal adenocarcinoma (PD AC)), comprising administering an anti-CD73 antibody or antigen binding fragment thereof and chemotherapy. The disclosure also relates to methods for the treatment of tumors comprising administering an anti-CD73 antibody or antigen-binding fragment thereof in combination with a PD-L1 antibody or an antigen-binding fragment thereof and chemotherapy.

WO 2022/064399 A1